Source: Annual Congress 2009 - Treatment of lung cancer
Disease area: Thoracic oncology

Abstract

Intensive chemotherapy regimens do effectively kill lung cancer cerlls. However, lung cancer cells are often resistance to chemotherapy and even develop acquired chemoresistance or show multi-drug resistance as a consequence of the previous treatment. TRAIL is a new proapoptotic cytokine. It is believed that TRAIL can selectively kill cancer cells but not normal cells. The aim of our study was to determine the effect of combination therapy with chemotherapeutic agents and TRAIL in different lung cancer cells lines and in vivo.
The sensitivity of NSCLC undergo apoptosis was assessed by MTT assay, DAPI assay and PI staining.
Firstly, we test the sensitivity of different cancer cells lines to TRAIL. Our results show that H460 is most sensitive to TRAIL; H1299 is most resistance to TRAIL. In the syngergistic effects of chemotherapeutic agents and TRAIL-induced apoptosis in NSCLC cell lines, there is also significant synergistic effect. Paclitabine enhances cytotoxic effect of TRAIL in 7 of 10 cell lines. Gemcitabine and TRAIL are synergistic in 6 of 10 NSCLC cell lines. Cisplatin and TRAIL are synergistic in 3 of 10 NSCLC cell lines. Finally, in vivo administration of paclitaxel and TRAIL substantially inhibited subcutaneous tumor growth of H460 cells.
Our results suggest that TRAIL is a promising anti-tumor cytokine that has significant synergistic effects with conventional chemotherapeutic drugs against human NSCLC.

Rating:

Share or cite this content

Citations should be made in the following way:
C. C. Tu, W. J. Wu (Taichung, Taiwan). Effects of chemotherapeutic drugs and TRAIL (tumor necrosis factor-related apoptosis inducing ligand) on the non-small lung cancer cells. Eur Respir J 2009; 34: Suppl. 53, 2641

Member's Comments

No comment yet.

Related content which might interest you: Mesenchymal stem cells reduce lung metastases by controlled targeted delivery of TNF-related apoptosis-inducing ligand (TRAIL) Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009 Oral presentation: Mesenchymal stem cells reduce lung metastases by controlled targeted delivery of TNF-related apoptosis-inducing ligand (TRAIL) Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009 Inhibition of proliferation of lung cancer cells by CD40 signaling through tumor necrosis factor I Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 The role of TNF-related apoptosis inducing ligand (TRAIL) in fibrotic lung disease Source: Annual Congress 2011 - Growth factors and fibrogenesis: are they good, bad or both? Year: 2011 Role of TNF-related apoptosis inducing ligand (TRAIL) in lung protective immunity against S. pneumoniae Source: Annual Congress 2010 - Mechanisms of respiratory infections Year: 2010 Gemcitabine sensitizes lung cancer cells to Fas /Fas ligand system-mediated killing Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 Some of the tumor necrosis factor receptor superfamilies and their concentrations in serum during chemotherapy of lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 102s Year: 2006 Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018 Year: 2019 Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker Source: International Congress 2019 – Biology of lung cancer Year: 2019 The death receptor Fas in CD3+T cells in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 673s Year: 2004 Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Source: Eur Respir J 2007; 30: 627-632 Year: 2007 Adenovirus-mediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis Source: Eur Respir J 2002; 20: 703-709 Year: 2002 Magnolol can induce apoptosis in non-small cell lung cancer via caspase-independent pathway Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Adenovirus-mediated interferon-beta gene therapy inhibits tumor growth and inhibits metastatic lung tumors in mice Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002 Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer Source: Eur Respir Rev 2010 19: 186-196 Year: 2010 Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Blocking VEGF does not induce proapoptotic effects in the NSCLC cell line A549 Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010 Deguelin enhances chemosensitivity of non-small cell lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 336s Year: 2006 Toll-like receptor 3 is up-regulated and enhances anti-proliferative function in human non-small cell lung cancer Source: Annual Congress 2008 - Lung cancer and other malignant diseases involving the lungs Year: 2008